Skip to main content

Metalyse_Banner

Single IV bolus administration

Metalyse® 25 mg is administered by a single IV bolus over 5 to 10 seconds, eliminating the need for a one-hour infusion, as required for Actilyse®1-3

Single IV bolus_administration 2

Metalyse® is quick and easy to use and does not require an infusion pump - simplifying preparation, saving time and cost, as well as reducing dosing errors*1-5

  • Metalyse® 25 

  • Metalyse® 25 mg comes as one single vial of powder for reconstitution, regardless of the patient

  • The dosing for Metalyse® 25 mg is simple with only 5
weight-based tiers:

metalyse-25-mg-is-administered-by-a-single-iv-bolus-injection
Weight (kg)Volume (ml)Tenecteplase (U)Tenecteplase (mg)
< 603300015
≥ 60 to < 703.5350017.5
≥ 70 to < 804400020
≥ 80 to <904.5450022.5
≥ 905500025
Actilyse_vs_Tenectaplase-4

Why is Metalyse® 25 mg quicker and easier to use compared to Actilyse®?

Tenecteplase is a genetically modified version of alteplase. Mutations in the protein sequence increased the specificity of Metalyse® (tenecteplase) to fibrin and made it more resistant to natural inhibitors, which increased its half-life and allowed for shorter treatment duration.6-7

Footnotes
  • IV: intravenous; PAI-1: plasminogen activator inhibitor-1
  • *
    One of the common contributing factors that led to dosing errors associated with alteplase administration was the infusion pump being programmed incorrectly. Additionally, a single IV bolus administration avoids the interruption of treatment, further reducing dosing errors.
  • †
    Tenecteplase was administrated within 4.5 hours after onset of stroke symptoms, as a weight-tiered bolus dose, based on 0.25 mg/kg by 10 kg steps, for the maximum weight at each tier: < 60 kg, 15 mg tenecteplase; ≥ 60 to < 70 kg, 17.5 mg; ≥ 70 to < 80 kg, 20 mg; ≥ 80 to < 90 kg, 22.5 mg; and ≥ 90 kg, 25 mg.
References
  • 1.
    Metalyse® Summary of Product Characteristics, January 2024.
  • 2.
    Menon BK, et al. Lancet 2022;400:161-169.
  • 3.
    Bivard A, et al. Lancet Neurol. 2022;21:520-27.
  • 4.
    Actilyse® European Summary of Product Characteristics.
  • 5.
    Dancsecs K. A. et al. Am J Emerg Med. 2021;47:90-94.
  • 6.
    Miller, SE and Warach, SJ. Neurotherapeutics 2023;20:664–678.
  • 7.
    Zhu A, et al. Res Pract Thromb Haemost. 2022;6:e12795.
  • 8.
    Huang X, et al. Stroke. 2015;46(12):3543–6.
  • 9.
    Tanswell P, et al. Clin Pharmacokinet. 2002;41(15):1229–45.

PC-AE-102393 | Expiry Date: 02/18/2029